The drug company Glaxo was unsuccessful in its attempt to combat wholesalers that purchase their drugs in Spain, and then turn around and sell them in countries like the UK, where the prices are higher.

In order to combat the problem Glaxo wanted to raise the prices for the drugs in Spain, which the European Commission did not approve. The resale of the drugs is estimated to cost the drug manufacturers billions of pounds every year.

Glaxo may have a small light still shining at the end of the tunnel however, as the European Court of Justice stated to EC regulators yesterday, that they may want to think about their ruling, due to the fact that the Commission may not have looked over the evidence presented by Glaxo in its entirety.